Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer

International Journal of Gynecological Cancer

Volumn 13, Issue 6, 2003, Pages 776-784

  Ikeda, K ^a   Sakai, K ^b   Yamamoto, R ^a   Hareyama, H ^b   Tsumura, N ^c   Watari, H ^a   Shimizu, M ^d   Minakami, H ^a   Sakuragi, N ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

^c Obihiro Kosei Hospital   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Clear cell adenocarcinoma; GST pi; MDR 1; Ovarian cancer; p53; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1242339599     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13381.x     Document Type: Article

References (45)

1. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
2. Sakuragi N, Yamada H, Oikawa M et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 2000;79:251-5.
3. Tammela J, Geisler JP, Eskew PN Jr, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998;19:438-40.
4. Lehne G, Elonen E, Baekelandt M, Skovsgaard T, Peterson C. Challenging drug resistance in cancer therapy - review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9 and 10th, 1997. Acta Oncol 1998;37:431-9.
5. Ban N, Takahashi Y, Takayama T et al. Transfection of glutathione S-transferase (GST) -pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996;56:3577-82.
6. Germain I, Tetu B, Brisson J, Mondor M, Cherian MG. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol 1996;15:54-62.
7. Wrigley EC, McGown AT, Buckley H, Hall A, Crowther D. Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Br J Cancer 1996;73:763-9.
8. van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-8.
9. Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol 1998;70:176-82.
10. Hirazono K, Shinozuka T, Kuroshima Y, Itoh H, Kawai K. Immunohistochemical expression of glutathione S-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors. J Obstet Gynaecol 1995;21:305-12.
11. Mayr D, Pannekamp U, Baretton GB et al. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 2000;196:469-75.
12. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996;32:1039-50.
13. Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000;20:1061-7.
14. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
15. Takahashi M, Tonoki H, Tada M et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92-9.
16. Buttitta F, Marchetti A, Gadducci A et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
17. Debernardis D, Sire EG, De Feudis P et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997;57:870-4.
18. Lavarino C, Pilotti S, Oggionni M et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000;18:3936-45.
19. Gadducci A, Cianci C, Cosio S et al. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 2000;20:4793-9.
20. Scully RE. Tumors of the ovary and maldeveloped gonads. In: Hartmann WH ed. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology, 1979:117-27.
21. Serov SF, Scully RE. Histological Typing of Ovarian Tumours. Geneva: World Health Organization, 1973.
22. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
23. Ghalia AA, Rabboh NA, el Shalakani A, Seada L, Khalifa A. Estimation of glutathione S-transferase and its Pi isoenzyme in tumor tissues and sera of patients with ovarian cancer. Anticancer Res 2000;20:1229-35.
24. Kase H, Kodama S, Nagai E, Tanaka K. Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytol 1998;42:1397-402.
25. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 1999;25:387-94.
26. Kodama J, Hayase R, Yoshinouchi M, Okuda H, Kudo T. Immunohistochemical analysis of P-glycoprotein expression in diverse histological types of epithelial ovarian tumors. Acta Med Okayama 1994;48:249-55.
27. Codegoni AM, Broggini M, Pitelli MR et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997;65:130-7.
28. Arao S, Suwa H, Mandai M et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 1994;54:1355-9.
29. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-7.
30. Esser P, Tervooren D, Heimann K et al. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthamol Vis Sci 1998;39:164-70.
31. Baak JP, Langley FA, Talerman A, Delemarre JF. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986;8:354-7.
32. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89:2006-17.
33. Ho ES, Lai CR, Hsieh YT et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001;80:189-93.
34. Righetti SC, Della Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
35. Schuyer M, van der Burg ME, Henzen-Logmans SC et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001;85:1359-67.
36. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 2003;9:1028-32.
37. Tanner B, Hengstler JG, Laubscher S et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997;74:438-42.
38. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6:2138-45. Review.
39. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-4.
40. Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Philadelphia: JB Lippincott, 1982:1226-63.
41. Onda T, Yoshikawa H, Yasugi T et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 1998;83:1555-60.
42. Tsumura N, Sakuragi N, Hareyama H et al. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 1998;79:526-30.
43. Monga M, Carmichael JA, Shelley WE et al. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991;43:195-7.
44. Le T, Krepart GV, Lotocki RJ, Heywood MS. Clinically apparent early stage invasive epithelial ovarian carcinoma: should all be treated similarly? Gynecol Oncol 1999;74:252-4.
45. Makar APh, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.